Adaptimmune Therapeutics (ADAP) News Today $0.28 +0.01 (+2.08%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.29 +0.01 (+2.46%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAP Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Two Seas Capital LP Invests $7.99 Million in Adaptimmune Therapeutics plc (NASDAQ:ADAP)Two Seas Capital LP purchased a new stake in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,835,146 shares of the biotechnologMay 23 at 8:10 AM | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Earns Buy Rating from Analysts at StockNews.comStockNews.com initiated coverage on shares of Adaptimmune Therapeutics in a research note on Friday. They set a "buy" rating on the stock.May 18, 2025 | marketbeat.comHC Wainwright Brokers Boost Earnings Estimates for ADAPMay 18, 2025 | americanbankingnews.comStockNews.com Initiates Coverage on Adaptimmune Therapeutics (NASDAQ:ADAP)May 18, 2025 | americanbankingnews.comLeerink Partnrs Has Bullish Estimate for ADAP Q2 EarningsMay 17, 2025 | americanbankingnews.comWells Fargo & Company Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $1.00May 17, 2025 | americanbankingnews.comBarclays Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $0.46May 17, 2025 | americanbankingnews.comAdaptimmune Therapeutics (NASDAQ:ADAP) Issues Earnings Results, Misses Expectations By $0.01 EPSAdaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%.May 15, 2025 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2025 Earnings Call TranscriptMay 14, 2025 | insidermonkey.comAdaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ...May 14, 2025 | finance.yahoo.comAdaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comA Look Ahead: Adaptimmune Therapeutics's Earnings ForecastMay 12, 2025 | benzinga.comAdaptimmune Q1 2025 Earnings PreviewMay 12, 2025 | msn.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have issueMay 12, 2025 | marketbeat.comAdaptimmune Therapeutics (ADAP) to Release Earnings on TuesdayAdaptimmune Therapeutics (NASDAQ:ADAP) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-13-adaptimmune-therapeutics-plc-stock/)May 11, 2025 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Down 15.8% in AprilAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the target of a large drop in short interest in April. As of April 15th, there was short interest totalling 4,590,000 shares, a drop of 15.8% from the March 31st total of 5,450,000 shares. Currently, 2.0% of the company's stock are short sold. Based on an average daily volume of 1,630,000 shares, the days-to-cover ratio is presently 2.8 days.May 5, 2025 | marketbeat.comAnalysts Conflicted on These Healthcare Names: QuidelOrtho (QDEL) and Enliven Therapeutics (ELVN)May 2, 2025 | theglobeandmail.comTwo Seas Capital LP Takes $7.99 Million Position in Adaptimmune Therapeutics plc (NASDAQ:ADAP)Two Seas Capital LP acquired a new position in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 14,835,146 shares of the biotechnology comApril 27, 2025 | marketbeat.comLong Focus Capital Management LLC Increases Stock Position in Adaptimmune Therapeutics plc (NASDAQ:ADAP)Long Focus Capital Management LLC boosted its position in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 54.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,494,393 shares of the biotechnology company's stock afApril 25, 2025 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at StockNews.comStockNews.com began coverage on Adaptimmune Therapeutics in a report on Tuesday. They set a "buy" rating on the stock.April 23, 2025 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Given Average Rating of "Moderate Buy" by BrokeragesShares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and foApril 17, 2025 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by Analysts at StockNews.comStockNews.com began coverage on Adaptimmune Therapeutics in a research report on Monday. They issued a "buy" rating for the company.April 15, 2025 | marketbeat.comAdaptimmune downgraded to Hold from Buy at JonesResearchApril 11, 2025 | markets.businessinsider.comEuropean Equities Traded in the US as American Depositary Receipts Fall in Thursday TradingApril 3, 2025 | msn.comWhat Analysts Are Saying About Adaptimmune Therapeutics StockApril 3, 2025 | nasdaq.comHC Wainwright Has Lowered Expectations for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock PriceHC Wainwright dropped their target price on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a research report on Tuesday.April 2, 2025 | marketbeat.comAdaptimmune price target lowered to $3 from $3.50 at H.C. WainwrightApril 1, 2025 | markets.businessinsider.com4ADAP : What Analysts Are Saying About Adaptimmune Therapeutics...April 1, 2025 | benzinga.comAdaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by StockNews.comStockNews.com assumed coverage on Adaptimmune Therapeutics in a report on Saturday. They issued a "buy" rating on the stock.March 30, 2025 | marketbeat.comAnalysts Set Expectations for ADAP Q1 EarningsAdaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Adaptimmune Therapeutics in a note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst J. Chang anticipates that the biotechnology company will earn ($0.10March 29, 2025 | marketbeat.comBarclays Remains a Sell on Adaptimmune Therapeutics (ADAP)March 28, 2025 | markets.businessinsider.comQ1 Earnings Estimate for ADAP Issued By Zacks Small CapAdaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Equities researchers at Zacks Small Cap issued their Q1 2025 EPS estimates for shares of Adaptimmune Therapeutics in a research report issued to clients and investors on Tuesday, March 25th. Zacks Small Cap analyst M. Kim anticipates thatMarch 28, 2025 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Given New $1.75 Price Target at GuggenheimGuggenheim dropped their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a report on Wednesday.March 27, 2025 | marketbeat.comAdaptimmune price target lowered to $1.75 from $3 at GuggenheimMarch 27, 2025 | markets.businessinsider.comAdaptimmune Therapeutics Amends Loan AgreementMarch 26, 2025 | investing.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | insidermonkey.comAdaptimmune Therapeutics (ADAP) Gets a Buy from ScotiabankMarch 25, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPSAdaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%.March 25, 2025 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Given Consensus Recommendation of "Moderate Buy" by AnalystsAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendatiMarch 22, 2025 | marketbeat.comWells Fargo & Company Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $1.50Wells Fargo & Company decreased their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research note on Friday.March 22, 2025 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Price Target Lowered to $1.40 at ScotiabankScotiabank dropped their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a research note on Friday.March 22, 2025 | marketbeat.comEarnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025March 22, 2025 | uk.investing.comAdaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | seekingalpha.comAdaptimmune price target lowered to $1.40 from $3.15 at ScotiabankMarch 22, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (ADAP) Receives a Buy from Mizuho SecuritiesMarch 21, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated by Analysts at StockNews.comStockNews.com started coverage on Adaptimmune Therapeutics in a report on Friday. They set a "buy" rating for the company.March 21, 2025 | marketbeat.comKSQ Therapeutics Appoints Kristen Hege, M.D., to its Board of DirectorsMarch 5, 2025 | markets.businessinsider.comAdaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are retail investors with 50% stake, while 25% is held by hedge fundsMarch 4, 2025 | finance.yahoo.comAdaptimmune Therapeutics (ADAP) Projected to Post Quarterly Earnings on WednesdayAdaptimmune Therapeutics (NASDAQ:ADAP) will be releasing earnings before the market opens on Wednesday, March 5, Financial Modeling Prep reports.February 26, 2025 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. lowered its stake in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 29.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,819,095 shares of the biotechnoloFebruary 19, 2025 | marketbeat.com Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAP Media Mentions By Week ADAP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADAP News Sentiment▼0.400.75▲Average Medical News Sentiment ADAP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADAP Articles This Week▼12▲ADAP Articles Average Week Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMMP News AURA News DBVT News HRTX News CMPX News ACB News ALMS News CADL News NGNE News TERN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADAP) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADAP Stock Free ADAP Stock Alerts